Anti-D immunoglobulin

Non-sensitised RhD-negative pregnancy with an indication for routine antenatal prophylaxis

IM or IV for this Rhophylac product only

Once at 28–30 weeks

One routine antenatal dose; sensitising events and birth are assessed separately · Ready-to-use prefilled syringe 300 micrograms/2 mL (1500 IU/2 mL); bring to room temperature and give slowly. Verify product, RhD status and antibody screen; do not confuse with newborn vitamin K

• Give to the mother, not the infant. Early-pregnancy losses have separate gestation/management criteria; do not apply the routine 28-week row to every miscarriage.

One 300-microgram syringe covers approximately 15 mL fetal RhD-positive red cells; additional dose depends on measured FMH, not an arbitrary universal ceiling

Non-sensitised RhD-negative mother after an RhD-positive birth

IM or IV for this Rhophylac product only

Once as soon as possible, ideally within 72 hours of birth

Postnatal episode; if >72 hours have elapsed, do not withhold—give as soon as possible and obtain specialist advice · Ready-to-use prefilled syringe 300 micrograms/2 mL (1500 IU/2 mL); bring to room temperature and give slowly. Verify product, RhD status and antibody screen; do not confuse with newborn vitamin K

• Give to the mother, not the infant. Early-pregnancy losses have separate gestation/management criteria; do not apply the routine 28-week row to every miscarriage.

One 300-microgram syringe covers approximately 15 mL fetal RhD-positive red cells; additional dose depends on measured FMH, not an arbitrary universal ceiling